Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Azo-PROTAC-5C |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC51H51ClN12O6S |
InChIKeyOGTSSFRBYDKZEX-OGAWRBAASA-N |
CAS Registry2377513-22-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myeloid Leukemia | Preclinical | China | 10 Mar 2020 |